文献速递类风湿关节炎

全身糖皮质激素对类风湿关节炎疼痛的疗效:系统文献综述与荟萃分析

The efficacy of systemic glucocorticosteroids for pain in rheumatoid arthritis: a systematic literature review and meta-analysis.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

口服糖皮质激素可降低自发性疼痛,合并标准化均数差(SMD)为-0.65(95%CI -0.82,-0.49,P<0.001),但疗效随用药时间延长而减弱,超过3个月后可能无法达到临床重要的疼痛缓解。

要点

  • 口服糖皮质激素对RA有镇痛作用,合并SMD为-0.65(95%CI -0.82,-0.49)。
  • 疼痛改善在用药早期最明显,≤3个月视觉模拟量表(VAS)疼痛平均差为-15 mm。
  • 超过3个月后疼痛获益减小,长期疼痛负担需考虑糖皮质激素以外的治疗。

核心结论

  • 口服糖皮质激素在RA中具有镇痛作用,但获益主要在开始治疗后短期内,超过3个月可能无法达到临床重要的疼痛缓解。

研究设计与样本

  • 系统文献综述与荟萃分析,检索三个数据库,纳入比较全身糖皮质激素与无活性治疗的RA随机对照试验(RCT),研究已预注册(PROSPERO CRD42019111562)。

主要发现

  • 口服糖皮质激素组自发性疼痛评分下降,SMD=-0.65(15项研究,95%CI -0.82,-0.49,P<0.001),异质性显著(I2=56%,P=0.0002)。
  • VAS疼痛平均差在≤3个月为-15 mm(95%CI -20,-9),>3-6个月为-8 mm(95%CI -12,-3),>6个月为-7 mm(95%CI -13,0),均显示糖皮质激素组优于对照。
  • 诱发性疼痛结局的检查获得类似结果;5项RCT的数据提示糖皮质激素治疗期间疲劳也有改善。

关键数值与推荐

  • 疼痛疗效以SMD=-0.65(15项研究,95%CI -0.82,-0.49,P<0.001)汇总,异质性I2=56%(P=0.0002)。
  • VAS疼痛平均差:≤3个月-15 mm(95%CI -20,-9),>3-6个月-8 mm(95%CI -12,-3),>6个月-7 mm(95%CI -13,0)。

临床怎么用

  • 对RA活动期疼痛可考虑短期使用口服糖皮质激素以获取镇痛获益。
  • 超过3个月仍需控制疼痛时,应考虑抗炎糖皮质激素以外的治疗以减轻长期疼痛负担。

局限性

  • 全文仅报告进行了异质性与发表偏倚评估(漏斗图、Egger检验)及亚组分析,未给出具体偏倚检验结果数值。
  • 纳入研究间存在显著异质性(I2=56%),可能影响合并效应量的解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Glucocorticosteroids (GCs) are recommended to suppress inflammation in people with active RA. This systematic review and meta-analysis aimed to quantify the effects of systemic GCs on RA pain. METHODS: A systematic literature review of randomized controlled trials (RCTs) in RA comparing systemic GCs to inactive treatment. Three databases were and spontaneous pain and evoked pain outcomes were extracted. Standardized mean differences (SMDs) and mean differences were meta-analysed. Heterogeneity (I2, tau statistics) and bias (funnel plot, Egger's test) were assessed. Subgroup analyses investigated sources of variation. This study was pre-registered (PROSPERO CRD42019111562). RESULTS: A total of 18 903 titles, 880 abstracts and 226 full texts were assessed. Thirty-three RCTs suitable for the meta-analysis included 3123 participants. Pain scores (spontaneous pain) decreased in participants treated with oral GCs; SMD = -0.65 (15 studies, 95% CI -0.82, -0.49, P <0.001) with significant heterogeneity (I2 = 56%, P =0.0002). Efficacy displayed time-related decreases after GC initiation. Mean difference visual analogue scale pain was -15 mm (95% CI -20, -9) greater improvement in GC than control at ≤3 months, -8 mm (95% CI -12, -3) at >3-6 months and -7 mm (95% CI -13, 0) at >6 months. Similar findings were obtained when evoked pain outcomes were examined. Data from five RCTs suggested improvement also in fatigue during GC treatment. CONCLUSION: Oral GCs are analgesic in RA. The benefit is greatest shortly after initiation and GCs might not achieve clinically important pain relief beyond 3 months. Treatments other than anti-inflammatory GCs should be considered to reduce the long-term burden of pain in RA.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. McWilliams DF, Thankaraj D, Jones-Diette J, et al. The efficacy of systemic glucocorticosteroids for pain in rheumatoid arthritis: a systematic literature review and meta-analysis. Rheumatology (Oxford). 2021. PMID: 34213524. doi:10.1093/rheumatology/keab503

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。